A novel antibody-drug conjugate can drastically reduce the risk of progression in HER2-low breast cancer, new Phase 3 data presented at the European Society of Molecular Oncology (ESMO) Congress has ...

Daraxonrasib received a standing ovation at the ASCO 2026 Annual Meeting, Breakthrough Therapy and Orphan Drug designations from the FDA, and global attention for effectively doubling survival in ...

JAK inhibitors should be an option for symptomatic myelofibrosis patients even if their disease is low risk, according to new guidelines from the American Society of Hematology (ASH). Published in ...

The Medical Services Advisory Committee has endorsed extending Medicare and PBS supervision criteria for extracorporeal photopheresis, opening the door for dermatologists to supervise the treatments.

There’s not enough good quality evidence to show medical cannabis delivers benefits for the treatment of insomnia, a panel of global researchers have found. The recently published Cochrane review ...

Researchers have developed a new risk stratification tool for patients with left-sided infective endocarditis (LSIE), to help inform MDT team discussions and assist with treatment decisions. The ...

Exposure to dupilumab during pregnancy for the treatment of asthma or atopic dermatitis does not increase risks of major birth defects or minor malformations for infants, according to a study ...

Hormone therapy triptorelin is now available on the PBS for a range of women’s health conditions, including breast cancer. The unrestricted listing from October 1 comes after a decision by AstraZeneca ...

Clinicians who fail to manage commercial conflicts of interest when treating patients face fines up of to $120,000, Ahpra has warned. The regulator has published new interim guidance for practitioners ...

Join an expert panel of QLD oncologists as they present their selection of transformational clinical data in breast, lung, GU, GI and skin cancers from the ESMO Congress 2026 and discuss the impacts ...

Rapid LDL cholesterol reduction with evolocumab before primary or urgent PCI will take years to translate into meaningful benefits, according to a new study. The French-led AMUNDSEN phase 4 clinical ...